NYSE:BMY News 2 December 2025

AbbVie Stock Week Ahead (Dec. 22–26, 2025): ABBV Holds Near $227 as Drug-Pricing Headlines Collide With Fresh Analyst Upgrades

As of Sunday, December 21, 2025, AbbVie Inc. (NYSE: ABBV) heads into a holiday-shortened trading week with shares hovering near the mid-$220s, after a high-volume rebound into Friday’s close. The setup for the week ahead is defined by two competing

21 December 2025

Pharma Stocks Week Ahead (Dec. 22–26, 2025): Drug-Pricing Deals, FDA Catalysts, and M&A to Watch

Christmas week is usually about thin liquidity and shorter trading hours, not blockbuster headlines. But pharma and biotech stocks head into the final full week of the year with a rare mix of policy shockwaves, deal-making, and FDA-driven volatility—all clustered

21 December 2025

Drug Pricing · FDA Updates · Mergers & Acquisitions · NASDAQ:AMGN · NASDAQ:GILD · NYSE:BMY · NYSE:GSK · NYSE:MRK · NYSE:NVS · NYSE:SNY · Pharma Stocks · Weekly Outlook

Healthcare Stocks News Today: Drug Pricing Shake-Up, Biotech M&A, IPO Momentum, and 2026 Outlook (Dec. 20, 2025)

As of December 20, 2025, healthcare stocks are heading into year-end with a rare mix of policy clarity and policy risk—often at the same time. In the past 48 hours, the sector has been hit by major U.S. drug-pricing announcements,

20 December 2025

Biotech · Drug Pricing · Healthcare · Market Outlook · NASDAQ:AMGN · NASDAQ:GILD · NYSE:BMY · NYSE:GSK · NYSE:MRK · NYSE:NVS · NYSE:SNY · Stock Market

Bristol-Myers Squibb (BMY) Stock News Today: BofA Upgrade, Dividend Momentum and 2026 Pipeline Catalysts in Focus (Dec. 16, 2025)

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on Tuesday, December 16, 2025, as investors weigh a fresh Bank of America upgrade, a renewed value debate around the stock’s multiple, and a growing list of 2026 pipeline catalysts

16 December 2025

Dividend Stocks · Investment Strategies · Market Analysis · NYSE:BMY · Pharma News · Stock Market

Bristol-Myers Squibb (BMY) Stock Jumps on Analyst Upgrades, Dividend Hike, and a Catalyst-Rich 2026: What Investors Need to Know on Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight on December 16, 2025, with the stock trading around $54.29, up roughly 3.6% on the session as optimism builds around Wall Street upgrades, a newly announced dividend increase, and a

16 December 2025

Analyst Ratings · Dividends · Investing · NYSE:BMY · Pharmaceutical Industry · Stock Market

Bristol-Myers Squibb (BMY) Stock After Hours: BofA Upgrade Sparks a Rally — What to Know Before the Market Opens Dec. 16, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is ending Monday’s session in the spotlight after a sharp, analyst-driven move that pushed the pharma giant higher into the close — and kept the shares firm in extended trading. After the closing bell on

16 December 2025

After Hours Trading · Investing · Market Analysis · NYSE:BAC · NYSE:BMY · Pharmaceutical Industry · Stock Market

Arcus Biosciences (RCUS) Stock News, Forecasts and Analyst Targets — Dec. 14, 2025 Update

Arcus Biosciences, Inc. (NYSE: RCUS) is ending the weekend under a bright—and volatile—spotlight after a major clinical-program reset triggered a sharp Friday selloff. As of Sunday, December 14, 2025, the last reported close was $21.53, down 14.36% from the prior

14 December 2025

Analyst Ratings · Biotech Stocks · Financial News · Investment Analysis · NYSE:BMY · NYSE:GILD · NYSE:RCUS · Stock Market

Bristol Myers Squibb (BMY) Stock Update – 7 December 2025: Alzheimer’s Trial Twist, ASH 2025 Pipeline Data and a $6.7 Billion Lawsuit

Bristol Myers Squibb (NYSE: BMY) has packed a lot into the first week of December 2025 – from a surprise update on a key Alzheimer’s drug trial to major hematology data at ASH 2025 and a legal setback over its

7 December 2025

Clinical Trials · Investment Analysis · Legal Issues · NYSE:BMY · Pharma News · Stock Market

Bristol Myers Squibb (BMY) Stock Today: Cobenfy Trial Twist, AI Drug Discovery Milestone and $6.7 Billion Lawsuit Shape the 2026 Outlook

As of December 4, 2025, Bristol Myers Squibb Company (NYSE: BMY) is back on the radar of growth, value and dividend investors. After a sharp rally this week driven by fresh news on its Alzheimer’s drug Cobenfy, an AI-enabled drug

4 December 2025

AI Technology · Investment Analysis · Legal News · NYSE:BMY · Pharmaceuticals · Stock Market

Bristol-Myers Squibb (BMY) Stock Surges on Cobenfy Trial Twist and AI Milestone: Full Outlook as of December 3, 2025

Bristol-Myers Squibb Company (NYSE: BMY) is back in the spotlight. On December 3, 2025, the pharma giant’s share price jumped more than 6% intraday to around $51.32, extending a multi‑day rebound driven by a mix of clinical trial news, AI‑driven

3 December 2025

Artificial Intelligence · Biotechnology · Investment Analysis · NYSE:BMY · Pharmaceutical News · Stock Market

Bristol-Myers Squibb (BMY) Stock Today: Celgene Lawsuit Shock, ASH 2025 Momentum and 2026 Forecasts

On December 2, 2025, Bristol-Myers Squibb (NYSE: BMY) found itself at the center of two very different storylines: a revived $6.7 billion Celgene lawsuit and strong hematology data at ASH 2025. Together with a hefty dividend and low valuation multiples,

3 December 2025

Biotech News · Investment Analysis · Lawsuits · NYSE:BMY · Pharmaceuticals · Stock Market

Bristol-Myers Squibb (BMY) Stock Today: Lawsuit Shock, Breyanzi Momentum and 2026 Forecast

Bristol-Myers Squibb (NYSE: BMY) has suddenly become one of the most eventful big pharma names to watch as of December 1, 2025. A major lawsuit has been allowed to proceed, new cell therapy approvals are landing, hematology data at ASH

2 December 2025

Investment Analysis · Lawsuits · Market Forecast · NYSE:BMY · Pharmaceutical Industry · Stocks

NYSE:BMY News 2 December 2025 - 21 December 2025